Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral an...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ca6b542bbbdb401981d02d6907e26979 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ca6b542bbbdb401981d02d6907e269792021-12-02T09:18:02ZInteraction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient1176-63281178-2021https://doaj.org/article/ca6b542bbbdb401981d02d6907e269792013-03-01T00:00:00Zhttp://www.dovepress.com/interaction-between-paliperidone-extended-release-and-ts-1reg-an-oral--a12352https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1. Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome ScaleYasui-Furukori NHashimoto KKubo KTomita TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 317-320 (2013) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Yasui-Furukori N Hashimoto K Kubo K Tomita T Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
description |
Norio Yasui-Furukori, Kojiro Hashimoto, Kazutoshi Kubo, Tetsu Tomita Department of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan Abstract: Until now there has been no information available on drug interaction between paliperidone and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative. The patient in the case presented here was a 39-year-old man with a 15-year history of schizophrenia. The patient's usual treatment of 2 mg/day of risperidone was changed to 3 mg/day of paliperidone extended release. He experienced worsening psychotic symptoms after switching from risperidone to paliperidone while he was also receiving TS-1. Retrospective analyses showed plasma concentration of paliperidone was consistently lower during the treatment with TS-1 than without TS-1. This case suggests there is drug interaction between paliperidone extended-release tablets and TS-1. Keywords: schizophrenia, antipsychotic, OROS, diarrhea, Positive and Negative Syndrome Scale |
format |
article |
author |
Yasui-Furukori N Hashimoto K Kubo K Tomita T |
author_facet |
Yasui-Furukori N Hashimoto K Kubo K Tomita T |
author_sort |
Yasui-Furukori N |
title |
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
title_short |
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
title_full |
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
title_fullStr |
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
title_full_unstemmed |
Interaction between paliperidone extended release and TS-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
title_sort |
interaction between paliperidone extended release and ts-1®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient |
publisher |
Dove Medical Press |
publishDate |
2013 |
url |
https://doaj.org/article/ca6b542bbbdb401981d02d6907e26979 |
work_keys_str_mv |
AT yasuifurukorin interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient AT hashimotok interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient AT kubok interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient AT tomitat interactionbetweenpaliperidoneextendedreleaseandts1ampreganoralanticancerdrugcontaininga5fluorouracilderivativeinaschizophrenicpatient |
_version_ |
1718398212072538112 |